{"id":"azd2811","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL215152","moleculeType":"Small molecule","molecularWeight":"507.57"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"AZD2811 works by selectively binding to the sphingosine-1-phosphate receptor 1 (S1P1), which is involved in the regulation of lymphocyte trafficking and immune responses. This mechanism of action is thought to contribute to its therapeutic effects in various diseases.","oneSentence":"AZD2811 is a small molecule that targets the S1P1 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:30:18.096Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsing forms of multiple sclerosis"}]},"trialDetails":[{"nctId":"NCT04745689","phase":"PHASE2","title":"Study of AZD2811 + Durvalumab in ES-SCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-02-23","conditions":"Small-Cell Lung Cancer","enrollment":31},{"nctId":"NCT03217838","phase":"PHASE1","title":"Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as Monotherapy or in Combination in Acute Myeloid Leukemia Participants.","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2017-07-31","conditions":"Acute Myeloid Leukaemia","enrollment":50},{"nctId":"NCT04525391","phase":"PHASE2","title":"AZD2811 and Durvalumab (MEDI4736) Combination Therapy in Relapsed Small Cell Lung Cancer","status":"TERMINATED","sponsor":"Se-Hoon Lee","startDate":"2020-09-18","conditions":"SCLC, Recurrent","enrollment":4},{"nctId":"NCT02579226","phase":"PHASE1","title":"A Phase I Study of Safety, Tolerability, and PK of AZD2811 in Patients With Advanced Solid Tumors.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-10-28","conditions":"Advanced Solid Tumours","enrollment":72},{"nctId":"NCT03366675","phase":"PHASE2","title":"AZD 2811 Monotherapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N3]","status":"TERMINATED","sponsor":"Samsung Medical Center","startDate":"2017-12-01","conditions":"Small Cell Lung Cancer","enrollment":15}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":13,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["AZD1152 hQPA","AZD1152 hydroxyl-quinazoline pyrazole anilide"],"phase":"phase_2","status":"active","brandName":"AZD2811","genericName":"AZD2811","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AZD2811 is a small molecule that targets the S1P1 receptor. Used for Relapsing forms of multiple sclerosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":4,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}